This article is more than 5 years old. Information may no longer be current.

Quantel's Optimis Fusion earns CE mark

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Quantel Medical announced the Optimis Fusion integrated laser platform received CE Mark approval. The fusion system combines advanced selective laser trabeculoplasty photoregeneration therapy and traditional YAG photodisruption treatments to offer surgeons a versatile arsenal for treating both cataract and glaucoma.

Chief Executive Officer Jean-Marc Gendre explained in a company press release, “This approval constitutes a critical milestone for our medical laser business. We are proud to introduce an engineering breakthrough, which enables infrared and visible green nanosecond pulses to be produced by a single dual-mode cavity, reducing complexity and resulting in a more elegant and up-to-date combo laser design.”

Quantel said in the release that it will begin commercialization in all CE Mark-approved countries immediately. The company anticipates U.S. Food and Drug Administration approval in 2014.